Methods of treatment using ammonia-scavenging drugs
View Patent ↗The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.
1. A method of treating a patient having a urea cycle disorder comprising (a) determining a target urinary phenylacetyl glutamine (PAGN) output (b) calculating an effective initial dosage of a phenylacetic acid (PAA) prodrug selected from glyceryl tri-[4-phenylbutyrate] (HPN-100) and phenylbutyric acid (PBA) or a pharmaceutically acceptable salt of PBA, wherein the effective dosage of PAA prodrug is calculated based on a mean conversion of PAA prodrug to urinary PAGN of about 60%; and (c) administering the effective initial dosage of PAA prodrug to the patient.
2. The method of claim 1 , wherein target urinary PAGN output is determined as a ratio of the concentration of urinary PAGN to urinary creatinine.
3. The method of claim 1 , wherein administration of the effective initial dosage of PAA prodrug produces a normal plasma ammonia level in the patient.
4. The method of claim 1 , wherein the target PAGN output takes into account the patient's dietary protein intake.
5. The method of claim 1 , wherein the target PAGN output takes into account the patient's residual urea synthesis capacity.
6. The method of claim 1 , wherein the PAA prodrug is HPN-100.
7. The method of claim 1 , wherein the pharmaceutically acceptable salt of PBA is sodium PBA.
8. A method of administering a phenylacetic acid (PAA) prodrug selected from glyceryl tri-[4-phenylbutyrate] (HPN-100) and phenylbutyric acid (PBA) or a pharmaceutically acceptable salt of PBA to a patient having a from urea cycle disorder comprising (a) administering a first dosage of the PAA prodrug; (b) determining urinary phenylacetyl glutamine (PAGN) excretion following administration of the first dosage of the PAA prodrug; (c) determining an effective dosage of the PAA prodrug based on the urinary PAGN excretion, wherein the effective dosage is based on a mean conversion of PAA prodrug to urinary PAGN of about 60%; and (d) administering the effective dosage to the patient.
9. The method of claim 8 , wherein urinary PAGN excretion is determined as a ratio of the concentration of urinary PAGN to urinary creatinine.
10. The method of claim 8 , wherein the pharmaceutically acceptable salt of PBA is sodium PBA.
11. The method of claim 8 , wherein the PAA prodrug is HPN-100.
12. The method of claim 8 , wherein administration of the effective dosage of PAA prodrug produces a normal plasma ammonia level in the patient.